<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371786</url>
  </required_header>
  <id_info>
    <org_study_id>060-102</org_study_id>
    <nct_id>NCT01371786</nct_id>
  </id_info>
  <brief_title>A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler</brief_title>
  <official_title>A Phase 1, Open Label, Two Period, Randomized, Cross Over Scintigraphy Study Assessing Nasal Deposition of a Single Dose of a Ciclesonide Radiolabeled Solution Following Nasal Inhalation of a Novel Nasal Metered Dose Inhaler (MDI) and of a Mometasone Furoate Monohydrate Radiolabeled Suspension Via an Aqueous (AQ) Nasal Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, single dose, single site, randomized, cross over study that will
      assess nasal deposition of radioactivity following nasal inhalation of a ciclesonide
      radiolabeled solution via a novel nasal Metered Dose Inhaler (MDI) and of a mometasone
      furoate monohydrate radiolabeled suspension via an aqueous nasal spray in approximately 10-14
      patients with symptomatic allergic rhinitis, aged 18-65 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label, single dose, single site, randomized, cross over study that will
      assess nasal deposition of radioactivity following nasal inhalation of a ciclesonide
      radiolabeled solution via a novel nasal MDI and of a mometasone furoate monohydrate
      radiolabeled suspension via an aqueous nasal spray in approximately 10 14 patients with
      symptomatic allergic rhinitis, aged 18 65 years. In order to ensure that patients will be
      symptomatic at the time of dosing, participants will be asked to withhold their usual
      treatments for perennial or seasonal allergic rhinitis, beginning at the Screening Visit
      until after Study Visit 3.

      Each patient will be randomly assigned to one of two treatment sequences. The two treatments
      in this study are a single dose (one 37 mcg actuation per nostril) of radiolabeled solution
      of ciclesonide nasal aerosol 74 µg (Regimen A) and a single dose (two 50 mcg actuations per
      nostril) of a radiolabeled suspension of mometasone aqueous nasal spray 200 µg (Regimen B).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Deposition of Radioactivity Within the Nasal Cavity as a Percent of Delivered Dose</measure>
    <time_frame>Day 1 at 2 minutes post dose</time_frame>
    <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) within the nasal cavity, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Deposition of Radioactivity Within the Nasopharynx as a Percent of Delivered Dose</measure>
    <time_frame>Day 1 at 2 minutes post-dose</time_frame>
    <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) within the nasopharynx, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deposition of Radioactivity Within the Nasal Cavity Over 10 Minutes as a Percent of Delivered Dose</measure>
    <time_frame>Average of 2, 4, 6, 8 and 10 minutes post dose</time_frame>
    <description>The scintigraphic measure of radioactivity deposited within the nasal cavity, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), over 10 minutes (at approximately 2 minute intervals post-dose) following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial Deposition of Radioactivity on Nasal Wipes as a Percent of Delivered Dose</measure>
    <time_frame>Day 1 at 2 minutes post-dose</time_frame>
    <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) on nasal wipes, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deposition of Radioactivity Within on Nasal Wipes Over 10 Minutes as a Percent of Delivered Dose</measure>
    <time_frame>Average of 2, 4, 6, 8, and 10 minutes post dose</time_frame>
    <description>The scintigraphic measure of radioactivity deposited on nasal wipes, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), over 10 minutes (at approximately 2 minute intervals post-dose) following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Allergic Rhinitis (AR)</condition>
  <arm_group>
    <arm_group_label>ciclesonide nasal aerosol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciclesonide nasal aerosol</intervention_name>
    <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
    <arm_group_label>ciclesonide nasal aerosol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone Aqueous (AQ) nasal spray</intervention_name>
    <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
    <arm_group_label>mometasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has give written informed consent and agrees to adhere to concomitant
             medication withholding periods, prior to participation.

          -  Patient is aged 18-65 years, inclusive.

          -  Patient has a Body Mass Index (BMI) of 18-30 kg/m2, inclusive

          -  Patient must be in general good health (defined as the absence of any clinically
             relevant abnormalities as determined by the Investigator) based on screening physical
             examination, medical history, and clinical laboratory values (Hematology, Chemistries
             and Urinalysis).

          -  A history of perennial or seasonal allergic rhinitis confirmed on GP report, or
             clinical diagnosis of perennial or seasonal allergic rhinitis confirmed at screening.

          -  A demonstrated sensitivity at the Screening visit, or within the 90 days prior to
             screening, to at least one allergen known to induce PAR (house dust mite, animal
             dander, cockroach, and molds) or SAR (grass pollen, tree pollen and weed pollen) using
             a 3 mm response to a standard skin prick test. The patient's positive allergen test
             must be consistent with the medical history of PAR/SAR.

          -  Must be willing and able to communicate and participate in the whole study.

          -  Patients must refrain from taking medication for allergic rhinitis, from Screening
             until completion of second dosing period.

          -  Patients, if female, must have a negative serum pregnancy test at screening. Females
             of childbearing potential must be instructed to and agree to avoid pregnancy during
             the study and must use an acceptable method of birth control:

               1. An oral contraceptive, an intrauterine device (IUD), implantable contraceptive,
                  transdermal or injectable contraceptive for at least 1 month prior to entering
                  the study with continued use throughout the study and for thirty days following
                  study participation.

               2. Barrier method of contraception, eg, condom and/or diaphragm with spermicide
                  while participating in the study.

               3. True abstinence, when this is in line with the preferred and usual lifestyle of
                  the patient (if the patient is usually not sexually active but becomes active,
                  they with their partner, must use an acceptable method of birth control).

        Exclusion Criteria:

          -  Female patient who is pregnant or lactating.

          -  Patient has radiation exposure from clinical trials, including that from the present
             study, excluding background radiation but including diagnostic X rays and other
             medical exposures, exceeding 5 mSv in the last twelve months or 10 mSv in the last
             five years. No occupationally exposed worker, as defined in the Ionising Radiation
             Regulations 1999, shall participate in the study.

          -  Patient has an abnormality on physical examination that, in the investigator's
             opinion, would affect nasal airway resistance, including: nasal jewelry or piercings;
             nasal pathology such as nasal polyps or other clinically significant respiratory tract
             malformations; recent nasal biopsy; nasal trauma; or nasal ulcers or perforations.

          -  Patient has a history of cocaine or glue sniffing.

          -  Nasal surgery and atrophic rhinitis or rhinitis medicamentosa are not permitted within
             the last 60 days prior to the Screening visit.

          -  Patient is a smoker (based on results of breath carbon monoxide testing at screening;
             ie, ≥10 ppm).

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta agonists and any controller drugs (eg, theophylline, leukotriene
             antagonists, etc.); intermittent use (less than or equal to 3 uses per week) of
             inhaled short acting beta agonists is acceptable. Use of short acting beta agonists
             for exercise induced bronchospasm will be allowed.

          -  Patient has a history of any chronic respiratory disorder including active or
             quiescent pulmonary tuberculosis.

          -  Patient has a history of adverse reaction or allergy to ciclesonide, mometasone, other
             corticosteroids, or formulation excipients.

          -  Patient has a Screening forced expiratory volume (FEV1) &lt;80% of the predicted value
             for their age, sex, height and race.

          -  Patient has had an upper respiratory tract infection (excluding otitis media) within
             14 days of first dosing period, or a lower respiratory tract infection within 3 months
             of the first study day.

          -  Previous participation in an intranasal ciclesonide HFA nasal aerosol study;
             participation in any investigational drug trial within the 60 days preceding the
             Screening visit or planned participation in another investigational drug trial at any
             time during this trial.

          -  History of alcohol or drug abuse within 2 years preceding the Screening visit.

          -  Study participation by clinical investigator site employees and/or their relatives or
             by more than one patient from the same household.

          -  Have any of the following conditions that are judged by the investigator to be
             clinically significant and/or affect the patients availability to participate in the
             clinical trial:

               -  impaired hepatic function including alcohol related liver disease or cirrhosis

               -  history of ocular disturbances, eg, glaucoma or posterior subcapsular cataracts

               -  any systemic infection including a history of a positive test for HIV, hepatitis
                  B or hepatitis C.

               -  hematological, hepatic, renal, endocrine (except for controlled diabetes mellitus
                  or postmenopausal symptoms or hypothyroidism)

               -  gastrointestinal disease

               -  malignancy (excluding basal cell carcinoma)

               -  current neuropsychological condition with or without drug therapy

               -  Any condition that, in the judgment of the investigator, would preclude the
                  patient from completing the protocol with capture of the assessments as written.

               -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per
                  week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington Fields</city>
        <state>Ruddington</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <results_first_submitted>August 3, 2012</results_first_submitted>
  <results_first_submitted_qc>August 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2012</results_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciclesonide</keyword>
  <keyword>Allergic Rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciclesonide Nasal Aerosol</title>
          <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
        </group>
        <group group_id="P2">
          <title>Mometasone</title>
          <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence Ciclesonide Nasal Aerosol /Mometsasone Aqueous</title>
          <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
        </group>
        <group group_id="B2">
          <title>Sequence Mometasone Aqueous / Ciclesonide Nasal Aerosol</title>
          <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canistermometasone Aqueous (AQ) nasal spray : A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="13.62"/>
                    <measurement group_id="B2" value="34.6" spread="11.96"/>
                    <measurement group_id="B3" value="35.4" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Initial Deposition of Radioactivity Within the Nasal Cavity as a Percent of Delivered Dose</title>
        <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) within the nasal cavity, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
        <time_frame>Day 1 at 2 minutes post dose</time_frame>
        <population>Scintigraphic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
          </group>
          <group group_id="O2">
            <title>Mometasone</title>
            <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Deposition of Radioactivity Within the Nasal Cavity as a Percent of Delivered Dose</title>
          <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) within the nasal cavity, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
          <population>Scintigraphic Population</population>
          <units>percentage of radiolabeled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.48" spread="0.98"/>
                    <measurement group_id="O2" value="86.28" spread="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal null hypothesis was stated or tested.Descriptive statistics only were calculated and presented. The sample size was determined outside of statistical considerations. The sample size of 10 subjects was sufficient to provide approximately 80% power to detect a difference of 25% between the two treatment groups in the percentage of nasal deposition approximately 2 minutes post dose, assuming a two-sided test evaluated at a significance level of 0.05, with a SD of the difference of 23.17%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.76</ci_lower_limit>
            <ci_upper_limit>-4.09</ci_upper_limit>
            <estimate_desc>Difference calculated as Mometasone minus Ciclesonide</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Deposition of Radioactivity Within the Nasopharynx as a Percent of Delivered Dose</title>
        <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) within the nasopharynx, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
        <time_frame>Day 1 at 2 minutes post-dose</time_frame>
        <population>Scintigraphic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
          </group>
          <group group_id="O2">
            <title>Mometasone</title>
            <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Deposition of Radioactivity Within the Nasopharynx as a Percent of Delivered Dose</title>
          <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) within the nasopharynx, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
          <population>Scintigraphic Population</population>
          <units>percentage of radiolabeled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.11"/>
                    <measurement group_id="O2" value="1.58" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deposition of Radioactivity Within the Nasal Cavity Over 10 Minutes as a Percent of Delivered Dose</title>
        <description>The scintigraphic measure of radioactivity deposited within the nasal cavity, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), over 10 minutes (at approximately 2 minute intervals post-dose) following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
        <time_frame>Average of 2, 4, 6, 8 and 10 minutes post dose</time_frame>
        <population>Scinitgraphic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
          </group>
          <group group_id="O2">
            <title>Mometasone</title>
            <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Deposition of Radioactivity Within the Nasal Cavity Over 10 Minutes as a Percent of Delivered Dose</title>
          <description>The scintigraphic measure of radioactivity deposited within the nasal cavity, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), over 10 minutes (at approximately 2 minute intervals post-dose) following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
          <population>Scinitgraphic Population</population>
          <units>percentage of of radiolabled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.61" spread="11.80"/>
                    <measurement group_id="O2" value="69.15" spread="18.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Deposition of Radioactivity on Nasal Wipes as a Percent of Delivered Dose</title>
        <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) on nasal wipes, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
        <time_frame>Day 1 at 2 minutes post-dose</time_frame>
        <population>Scintigraphic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
          </group>
          <group group_id="O2">
            <title>Mometasone</title>
            <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Deposition of Radioactivity on Nasal Wipes as a Percent of Delivered Dose</title>
          <description>The scintigraphic measure of radioactivity initially deposited (approximately 2 minutes post-dose) on nasal wipes, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
          <population>Scintigraphic Population</population>
          <units>percentage of radiolabeled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.98"/>
                    <measurement group_id="O2" value="12.15" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deposition of Radioactivity Within on Nasal Wipes Over 10 Minutes as a Percent of Delivered Dose</title>
        <description>The scintigraphic measure of radioactivity deposited on nasal wipes, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), over 10 minutes (at approximately 2 minute intervals post-dose) following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
        <time_frame>Average of 2, 4, 6, 8, and 10 minutes post dose</time_frame>
        <population>Scinitigraphic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
          </group>
          <group group_id="O2">
            <title>Mometasone</title>
            <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Deposition of Radioactivity Within on Nasal Wipes Over 10 Minutes as a Percent of Delivered Dose</title>
          <description>The scintigraphic measure of radioactivity deposited on nasal wipes, expressed as a percent of the delivered dose (i.e., the total amount of radioactivity delivered), over 10 minutes (at approximately 2 minute intervals post-dose) following nasal inhalation of a ciclesonide radiolabeled solution via a novel nasal MDI and a mometasone radiolabeled suspension via an aqueous nasal spray.</description>
          <population>Scinitigraphic Population</population>
          <units>percentage of radiolabeled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="1.71"/>
                    <measurement group_id="O2" value="13.15" spread="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ciclesonide Nasal Aerosol</title>
          <description>A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister</description>
        </group>
        <group group_id="E2">
          <title>Mometasone</title>
          <description>A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Both the formulations used in this study were radiolabeled and not the individual corticosteroid molecules. Therefore the distribution of the corticosteroid molecules over 10 minutes post-administration was not quantified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

